Spyre Therapeutics

Spyre Therapeutics

Spyre Therapeutics was founded in 2015 by Shep Perkins, who spent the prior decade as a portfolio manager at Fidelity Investments focused on healthcare and biotech. The firm emerged from Perkins' track record of concentrated bets on drug developers approaching regulatory catalysts, a style he refined managing Fidelity's healthcare select funds. Spyre operates as an investment adviser registered in New York, though its legal structure and limited partner base remain private. The firm pursues a concentrated, long-biased equity strategy within the biotechnology and specialty pharmaceuticals space. Rather than spreading capital across dozens of names, Spyre typically holds five to eight core positions, each sized to move the portfolio materially. The firm tends to enter positions well ahead of pivotal clinical trial readouts, holding through binary events that deter generalist investors. Spyre's engagement model blends public-market investing with direct board-level influence, often working with management teams to shape clinical strategy and capital allocation. The firm has disclosed past positions in Axsome Therapeutics, Intra-Cellular Therapies, and Karuna Therapeutics, with an investment horizon typically spanning two to four years (per SEC filings, 2023). Since its founding, Spyre has grown to manage a portfolio estimated in the mid-hundreds of millions, with Perkins remaining the sole CIO directing all investment decisions. The firm's lean team operates out of a single New York office. While Spyre maintains no formally disclosed adjacent vehicles, Perkins' reputation has attracted capital from endowments and family offices seeking concentrated healthcare exposure. In 2023, Perkins appeared on the Barron's list of the most influential investors in biotech, reflecting the firm's ability to impact company trajectories through activist positioning and public shareholder letters. Spyre occupies a rare structural niche—an activist concentrated fund in an asset class where passive and highly diversified approaches dominate. Most biotech hedge funds hedge clinical risk with broad baskets or pair trades; Spyre runs unhedged, single-name conviction. This architecture means the firm's annual returns can swing dramatically on individual FDA decisions, a volatility model that few institutional allocators accept but that has generated outsized returns in the zero-rate era's high-beta biotech cycles.